Undifferentiated Uterine Sarcoma With SMARCA4 Gene Deletion: Report of Two Cases and Literature Review

Shunxi DU; Hongying YANG

doi:10.3881/j.issn.1000-503X.16380

PDF(1727 KB)

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (6) : 1051-1056. DOI: 10.3881/j.issn.1000-503X.16380

Case Reports

Undifferentiated Uterine Sarcoma With SMARCA4 Gene Deletion: Report of Two Cases and Literature Review

Shunxi DU ,
Hongying YANG

Author information +

History +

Abstract

Undifferentiated uterine sarcoma with SMARCA4 gene deletion is a rare malignant tumor.The incidence of this type of tumor is low,and fewer than 40 cases have been reported worldwide.Most of the cases are advanced at the time of diagnosis,and the tumor is aggressive and difficult to be diagnosed.The lack of large-sample studies,unclear treatment plan,and individualized treatment in most cases lead to poor prognosis and high mortality.We report two cases of undifferentiated uterine sarcoma at the ⅣB stage in young women with SMARCA4 gene deletion,providing reference for future treatment.

Key words

SMARCA4 gene deletion / undifferentiated uterine sarcoma / small cell carcinoma of the ovary,hypercalcemic type

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Shunxi DU , Hongying YANG. Undifferentiated Uterine Sarcoma With SMARCA4 Gene Deletion: Report of Two Cases and Literature Review[J]. Acta Academiae Medicinae Sinicae. 2025, 47(6): 1051-1056 https://doi.org/10.3881/j.issn.1000-503X.16380

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas[J]. J Int Obstet Gynecol, 2018, 143:51-58.DOI:10.1002/ijgo.12613. Cited in this article [1]

[2]	樊蕊蕊, 高杰. SMARCA4缺失型子宫未分化肉瘤的临床病理及免疫微环境检测的研究进展[J]. 临床与实验病理学杂志, 2022, 38(7):847-849.DOI:10.13315/j.cnki.cjcep.2022.07.015. Cited in this article [1]

[3]	Kolin DL, Dong F, Baltay M, et al. SMARCA4-deficient undifferentiated uterine sarcoma(malignant rhabdoid tumor of the uterus):a clinicopathologic entity distinct from undifferentiated carcinoma[J]. Mod Pathol, 2018, 31(9):1442-1456.DOI:10.1038/s41379-018-0049-z. Cited in this article [1]

[4]	Kord A, Eppurath A, Drammeh H, et al. SMARCA4-deficient uterine sarcoma:a case report and a concise review[J]. Case Rep Womens Health, 2020, 27:e00231.DOI:10.1016/j.crwh.2020.e00231. Cited in this article [4]

[5]

Connor

, Miao

, Lin

, et al. Germline mutations of SMARCA4 in small cell carcinoma of the ovary,hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma:clinical features of a single family and comparison of large cohorts[J]. Gynecol Oncol, 2020, 157(1):106-114.DOI:10.1016/j.ygyno.2019.10.031.

Cited in this article [1]

[6]	Lin D, Allen J, Hecht J, et al. SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association[J]. Modern Pathol, 2019, 32(11):1675-1687.DOI:10.1038/s41379-019-0303-z. Cited in this article [2]

[7]	Kolin DL, Quick CM, Dong F, et al. SMARCA4-deficient uterine sarcoma and undifferentiated endometrial carcinoma are distinct clinicopathologic entities[J]. Am J Surg Pathol, 2020, 44(2):263-270.DOI:10.1097/PAS.0000000000001375. Cited in this article [2]

[8]	Howitt BE, Sholl LM, Dal Cin P, et al. Targeted genomic analysis of Müllerian adenosarcoma[J]. J Pathol, 2015, 235(1):37-49.DOI:10.1002/path.4442. Cited in this article [1]

[9]	Lang JD, Hendricks WPD, Yin H, et al. Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type(SCCOHT)through multi-kinase inhibition[J]. Clin Cancer Res, 2018, 24(8):1932-1943.DOI:10.1158/1078-0432.CCR-17-1928. Cited in this article [1]

[10]	Stewart BD, Kaye F, Machuca T, et al. SMARCA4-deficient thoracic sarcoma:a case report and review of literature[J]. Int J Surg Pathol, 2020, 28(1):102-108.DOI:10.1177/1066896919865944. Cited in this article [1]

[11]	Gadducci A, Cosio S, Romanini A, et al. The management of patients with uterine sarcoma:a debated clinical challenge[J]. Critcal Oncol Hemat, 2008, 65(2):129-142.DOI:10.1016/j.critrevonc.2007.06.011. Cited in this article [1]

[12]	Leyvraz S, Bacchi M, Cerny T, et al. Phase Ⅰ multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas[J]. Ann Oncol, 1998, 9(8):877-884.DOI:10.1023/A:1008464504583. Cited in this article [1]

[13]	Xue Y, Meehan B, Fu Z, et al. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer[J]. Nat Commun, 2019, 10(1):557.DOI:10.1038/s41467-019-08380-1. Cited in this article [1]

[14]	Xue Y, Meehan B, Macdonald E, et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary[J]. Nat Commun, 2019, 10(1):558.DOI:10.1038/s41467-018-06958-9. Cited in this article [1]

[15]

Chan-Penebre

, Armstrong

, Drew

, et al. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary,hypercalcemic type cells by inhibition of EZH2:in vitro and in vivo preclinical models[J]. Mol Cancer Ther, 2017, 16(5):850-860.DOI:10.1158/1535-7163.MCT-16-0678.

Cited in this article [1]

[16]	taliano A, Soria JC, Toulmonde M, et al. Tazemetostat,an EZH2 inhibitor,in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours:a first-in-human,open-label,phase 1 study[J]. Lancet Oncol, 2018,19(5):649-659.DOI:10.1016/S1470- 2045(18)30145-1. Cited in this article [1]

[17]	Wilson BG, Roberts CWM. SWI/SNF nucleosome remodellers and cancer[J]. Nat Rew Cancer, 2011, 11(7):481-492.DOI:10.1038/nrc3068. Cited in this article [1]

[18]	郭珊珊, 高萌, 陈文文, 等. SMARCA4缺失的肿瘤2例并文献回顾[J]. 中国临床研究, 2021, 34(6):811-814.DOI:10.13429/j.cnki.cjcr.2021.06.021. Cited in this article [1]

[19]	Pautier P, Nam EJ, Provencher DM, et al. Gynecologic Cancer InterGroup(GCIG)consensus review for high-grade undifferentiated sarcomas of the uterus[J]. Int J Gynecol Cancer, 2014, 24(9 Suppl 3):S73-S77.DOI:10.1097/IGC.0000000000000281. Cited in this article [1]